BBIO — BridgeBio Pharma Share News
0.000.00%
Last trade - 00:00- $13.12bn
- $15.77bn
- $502.08m
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics
Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say
Trump administration announces drug pricing deals with CSL, Astellas and others (updated)
Brief: BridgeBio Announces Agreement With U.S. Govt To Improve Affordability & Access To Critical Medicines
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Brief: Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
BridgeBio Pharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
BridgeBio Pharma's Q2 revenue beats on higher Attruby sales
BridgeBio Pharma, Inc. expected to post a loss of 58 cents a share - Earnings Preview
Brief: Bridgebio Pharma Inc Files For Offering Of Up To 24.6 Million Common Shares By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP- Anterix, Fidus Investment, Nextpower